Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis
- PMID: 19237648
- PMCID: PMC2681553
- DOI: 10.1128/AAC.01197-08
Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis
Abstract
The emergence of Mycobacterium tuberculosis resistant to first-line antibiotics has renewed interest in second-line antitubercular agents. Here, we aimed to extend our understanding of the mechanisms underlying para-aminosalicylic acid (PAS) resistance by analysis of six genes of the folate metabolic pathway and biosynthesis of thymine nucleotides (thyA, dfrA, folC, folP1, folP2, and thyX) and three N-acetyltransferase genes [nhoA, aac(1), and aac(2)] among PAS-resistant clinical isolates and spontaneous mutants. Mutations in thyA were identified in only 37% of the clinical isolates and spontaneous mutants. Overall, 24 distinct mutations were identified in the thyA gene and 3 in the dfrA coding region. Based on structural bioinformatics techniques, the altered ThyA proteins were predicted to generate an unfolded or dysfunctional polypeptide. The MIC was determined by Bactec/Alert and dilution assay. Sixty-three percent of the PAS-resistant isolates had no mutations in the nine genes considered in this study, revealing that PAS resistance in M. tuberculosis involves mechanisms or targets other than those pertaining to the biosynthesis of thymine nucleotides. The alternative mechanism(s) or pathway(s) associated with PAS resistance appears to be PAS concentration dependent, in marked contrast to thyA-mutated PAS-resistant isolates.
Figures



Comment in
-
Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.Antimicrob Agents Chemother. 2010 Oct;54(10):4522-3; author reply 5423-5. doi: 10.1128/AAC.00422-10. Antimicrob Agents Chemother. 2010. PMID: 20852189 Free PMC article. No abstract available.
Similar articles
-
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.Ann Clin Microbiol Antimicrob. 2022 Nov 5;21(1):48. doi: 10.1186/s12941-022-00537-z. Ann Clin Microbiol Antimicrob. 2022. PMID: 36335391 Free PMC article.
-
[Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis].Zhonghua Jie He He Hu Xi Za Zhi. 2007 Sep;30(9):683-5. Zhonghua Jie He He Hu Xi Za Zhi. 2007. PMID: 18070553 Chinese.
-
The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.Mol Microbiol. 2004 Jul;53(1):275-82. doi: 10.1111/j.1365-2958.2004.04120.x. Mol Microbiol. 2004. PMID: 15225321
-
Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.Antimicrob Agents Chemother. 2015 Sep;59(9):5097-106. doi: 10.1128/AAC.00647-15. Epub 2015 Jun 1. Antimicrob Agents Chemother. 2015. PMID: 26033719 Free PMC article. Review.
-
The aminosalicylate - folate connection.Drug Metab Rev. 2024 Feb;56(1):80-96. doi: 10.1080/03602532.2024.2303507. Epub 2024 Jan 17. Drug Metab Rev. 2024. PMID: 38230664 Free PMC article. Review.
Cited by
-
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations.Ann Clin Microbiol Antimicrob. 2022 Nov 5;21(1):48. doi: 10.1186/s12941-022-00537-z. Ann Clin Microbiol Antimicrob. 2022. PMID: 36335391 Free PMC article.
-
Whole genome sequencing reveals candidate genes involving in PAS resistance in M. Tuberculosis isolated from patients in Thailand.World J Microbiol Biotechnol. 2023 Dec 7;40(1):32. doi: 10.1007/s11274-023-03834-7. World J Microbiol Biotechnol. 2023. PMID: 38057660
-
Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.Cell Chem Biol. 2019 Jun 20;26(6):781-791.e6. doi: 10.1016/j.chembiol.2019.02.013. Epub 2019 Mar 28. Cell Chem Biol. 2019. PMID: 30930162 Free PMC article.
-
Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach.Int J Mol Sci. 2021 Dec 9;22(24):13259. doi: 10.3390/ijms222413259. Int J Mol Sci. 2021. PMID: 34948055 Free PMC article. Review.
-
Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.Front Cell Infect Microbiol. 2018 Apr 10;8:114. doi: 10.3389/fcimb.2018.00114. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 29755957 Free PMC article. Review.
References
-
- Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410. - PubMed
-
- Bifani, P., B. Mathema, N. E. Kurepina, E. Shashkina, J. Quatannens, A. S. Blanchis, S. Moghazeh, J. Driscoll, B. Gicquel, R. Frothingham, and B. N. Kreiswirth. 2008. The evolution of drug-resistance in Mycobacterium tuberculosis: from a mono-rifampin resistant cluster into increasingly multidrug resistant variants in an HIV sero-positive population. J. Infect. Dis. 198:90-94. - PubMed
-
- CDC. 1992. Update: availability of streptomycin and para-aminosalicylic acid—Unites States. MMWR Morb. Mortal. Wkly. Rep. 41:482.
-
- De Logu, A., V. Onnis, B. Saddi, C. Congiu, M. L. Schivo, and M. T. Cocco. 2002. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J. Antimicrob. Chemother. 49:275-282. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases